|
1
|
Wilkinson L and Gathani T: Understanding
breast cancer as a global health concern. Br J Radiol.
95:202110332022. View Article : Google Scholar
|
|
2
|
DeSantis CE, Ma J, Gaudet MM, Newman LA,
Miller KD, Goding Sauer A, Jemal A and Siegel RL: Breast cancer
statistics, 2019. CA Cancer J Clin. 69:438–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arnold M, Morgan E, Rumgay H, Mafra A,
Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S
and Soerjomataram I: Current and future burden of breast cancer:
Global statistics for 2020 and 2040. Breast. 66:15–23. 2022.
View Article : Google Scholar
|
|
4
|
Burstein HJ, Curigliano G, Thürlimann B,
Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP and Gnant M;
Panelists of the St Gallen Consensus Conference, : Customizing
local and systemic therapies for women with early breast cancer:
The St. Gallen International Consensus Guidelines for treatment of
early breast cancer 2021. Ann Oncol. 32:1216–1235. 2021. View Article : Google Scholar
|
|
5
|
Abu Samaan TM, Samec M, Liskova A, Kubatka
P and Büsselberg D: Paclitaxel's mechanistic and clinical effects
on breast cancer. Biomolecules. 9:7892019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dan VM, Raveendran RS and Baby S:
Resistance to intervention: Paclitaxel in breast cancer. Mini Rev
Med Chem. 21:1237–1268. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Lun X and Guo W: Expression of
TRPC1 and SBEM protein in breast cancer tissue and its relationship
with clinicopathological features and prognosis of patients. Oncol
Lett. 20:3922020.
|
|
8
|
Hao H, Yang L, Wang B, Sang Y and Liu X:
Small breast epithelial mucin as a useful prognostic marker for
breast cancer patients. Open Life Sci. 18:202207842023. View Article : Google Scholar
|
|
9
|
Hao H, Wang B, Yang L, Sang Y, Xu W, Liu
W, Zhang L and Jiang D: miRNA-186-5p inhibits migration, invasion
and proliferation of breast cancer cells by targeting SBEM. Aging
(Albany NY). 15:6993–7007. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li QH, Liu ZZ, Ge Y, Liu X, Xie XD, Zheng
ZD, Ma YH and Liu B: Small breast epithelial mucin promotes the
invasion and metastasis of breast cancer cells via promoting
epithelial-to-mesenchymal transition. Oncol Rep. 44:509–518. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu ZZ, Xie XD, Qu SX, Zheng ZD and Wang
YK: Small breast epithelial mucin (SBEM) has the potential to be a
marker for predicting hematogenous micrometastasis and response to
neoadjuvant chemotherapy in breast cancer. Clin Exp Metastasis.
27:251–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M,
Qin Y, Sun K, Teng Y and Liu M: Cancer-associated fibroblast
(CAF)-derived IL32 promotes breast cancer cell invasion and
metastasis via integrin β3-p38 MAPK signalling. Cancer Lett.
442:320–332. 2019. View Article : Google Scholar
|
|
13
|
Butti R, Das S, Gunasekaran VP, Yadav AS,
Kumar D and Kundu GC: Receptor tyrosine kinases (RTKs) in breast
cancer: Signaling, therapeutic implications and challenges. Mol
Cancer. 17:342018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren C, Han X, Lu C, Yang T, Qiao P, Sun Y
and Yu Z: Ubiquitination of NF-κB p65 by FBXW2 suppresses breast
cancer stemness, tumorigenesis, and paclitaxel resistance. Cell
Death Differ. 29:381–392. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Y, Pang J, Liu H, Cui W, Cao J and
Shi G: Fibronectin type III domain-containing protein 5 promotes
autophagy via the AMPK/mTOR signaling pathway in hepatocellular
carcinoma cells, contributing to nab-paclitaxel chemoresistance.
Med Oncol. 40:532022. View Article : Google Scholar
|
|
16
|
Zhao PW, Cui JX and Wang XM: Upregulation
of p300 in paclitaxel-resistant TNBC: Implications for cell
proliferation via the PCK1/AMPK axis. Pharmacogenomics J. 24:52024.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abedini MR, Muller EJ, Bergeron R, Gray DA
and Tsang BK: Akt promotes chemoresistance in human ovarian cancer
cells by modulating cisplatin-induced, p53-dependent ubiquitination
of FLICE-like inhibitory protein. Oncogene. 29:11–25. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Caunt CJ and Keyse SM: Dual-specificity
MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase
signalling. FEBS J. 280:489–504. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roux PP and Blenis J: ERK and p38
MAPK-activated protein kinases: A family of protein kinases with
diverse biological functions. Microbiol Mol Biol Rev. 68:320–344.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hoornaert I, Marynen P, Goris J, Sciot R
and Baens M: MAPK phosphatase DUSP16/MKP-7, a candidate tumor
suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced
transformation. Oncogene. 22:7728–7736. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Low HB and Zhang Y: Regulatory roles of
MAPK phosphatases in cancer. Immune Netw. 16:85–98. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu H, Tran L, Park Y, Chen I, Lan J, Xie Y
and Semenza GL: Reciprocal regulation of DUSP9 and DUSP16
expression by HIF1 controls ERK and p38 MAP kinase activity and
mediates chemotherapy-induced breast cancer stem cell enrichment.
Cancer Res. 78:4191–4202. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Keyse SM: Dual-specificity MAP kinase
phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27:253–261.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Polák L, Škoda P, Riedlová K, Krivák R,
Novotný M and Hoksza D: PrankWeb 4: A modular web server for
Protein-ligand binding site prediction and downstream analysis.
Nucleic Acids Res. 53:W466–W471. 2025. View Article : Google Scholar
|
|
26
|
Shi Y, Wang J, Tao S, Zhang S, Mao L, Shi
X, Wang W, Cheng C, Shi Y and Yang Q: miR-142-3p improves
paclitaxel sensitivity in resistant breast cancer by inhibiting
autophagy through the GNB2-AKT-mTOR pathway. Cell Signal.
103:1105662023. View Article : Google Scholar
|
|
27
|
Mishra T, Gupta S, Rai P, Khandelwal N,
Chourasiya M, Kushwaha V, Singh A, Varshney S, Gaikwad AN and
Narender T: Anti-adipogenic action of a novel oxazole derivative
through activation of AMPK pathway. Eur J Med Chem. 262:1158952023.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu Y, Wang A, Zhang S, Kim J, Xia J,
Zhang F, Wang D, Wang Q and Wang J: Paclitaxel-loaded ginsenoside
Rg3 liposomes for drug-resistant cancer therapy by dual targeting
of the tumor microenvironment and cancer cells. J Adv Res.
49:159–173. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fleisher TA: Apoptosis. Ann Allergy Asthma
Immunol. 78:245–950. 1997. View Article : Google Scholar
|
|
31
|
Wu M, Xue L, Chen Y, Tang W, Guo Y, Xiong
J, Chen D, Zhu Q, Fu F and Wang S: Inhibition of checkpoint kinase
prevents human oocyte apoptosis induced by chemotherapy and allows
enhanced tumour chemotherapeutic efficacy. Hum Reprod.
38:1769–1783. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang BR, Han JB, Jiang Y, Xu S, Yang R,
Kong YG, Tao ZZ, Hua QQ, Zou Y and Chen SM: CENPN suppresses
autophagy and increases paclitaxel resistance in nasopharyngeal
carcinoma cells by inhibiting the CREB-VAMP8 signaling axis.
Autophagy. 20:329–348. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Habib TN, Altonsy MO, Ghanem SA, Salama MS
and Hosny MA: Optimizing combination therapy in prostate cancer:
Mechanistic insights into the synergistic effects of Paclitaxel and
Sulforaphane-induced apoptosis. BMC Mol Cell Biol. 25:52024.
View Article : Google Scholar
|
|
34
|
Lin YW, Lin TT, Chen CH, Wang RH, Lin YH,
Tseng TY, Zhuang YJ, Tang SY, Lin YC, Pang JY, et al: Enhancing
efficacy of Albumin-bound paclitaxel for human lung and colorectal
cancers through autophagy receptor sequestosome 1
(SQSTM1)/p62-mediated nanodrug delivery and cancer therapy. ACS
Nano. 17:19033–19051. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Albuquerque T, Neves AR, Paul M, Biswas S,
Vuelta E, García-Tuñón I, Sánchez-Martin M, Quintela T and Costa D:
A Potential effect of circadian rhythm in the Delivery/therapeutic
performance of Paclitaxel-dendrimer nanosystems. J Funct Biomater.
14:3622023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim JH, Lee JO, Kim N, Lee HJ, Lee YW, Kim
HI, Kim SJ, Park SH and Kim HS: Paclitaxel suppresses the viability
of breast tumor MCF7 cells through the regulation of EF1α and
FOXO3a by AMPK signaling. Int J Oncol. 47:1874–1880. 2015.
View Article : Google Scholar
|
|
37
|
Tang Z, Zhang Y, Yu Z and Luo Z: Metformin
suppresses stemness of Non-small-cell lung cancer induced by
paclitaxel through FOXO3a. Int J Mol Sci. 24:166112023. View Article : Google Scholar
|
|
38
|
Yuan J, Dong X, Yap J and Hu J: The MAPK
and AMPK signalings: Interplay and implication in targeted cancer
therapy. J Hematol Oncol. 13:1132020. View Article : Google Scholar
|
|
39
|
Chu J, Panfen E, Wang L, Marino A, Chen
XQ, Fancher RM, Landage R, Patil O, Desai SD, Shah D, et al:
Evaluation of encequidar as an intestinal P-gp and BCRP specific
inhibitor to assess the role of intestinal P-gp and BCRP in
Drug-drug interactions. Pharm Res. 40:2567–2584. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rieske P, Krynska B and Azizi SA: Human
Fibroblast-derived cell lines have characteristics of embryonic
stem cells and cells of Neuro-ectodermal origin. Differentiation.
73:474–483. 2005. View Article : Google Scholar : PubMed/NCBI
|
